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Use of sirolimus and low-dose calcineurin inhibitor in lung
transplant recipients with renal impairment: Results of a con-
trolled pilot study.
Background. Renal failure induced by calcineurin-inhibitor
agents is a common complication of lung transplantation.
Sirolimus, a macrolide immunosuppressant with a distinct
mechanism of action, may prevent renal failure but was found
to have a high infectious and toxicity rate in the only relevant
study conducted so far. The aim of the present prospective pi-
lot study was to assess the benefit of sirolimus combined with
low-dose calcineurin inhibitors in this patient population.
Methods. Sixteen lung transplant recipients with post-
transplantation renal dysfunction were allocated to receive
the standard immunosuppression regimen or a combina-
tion sirolimus/low-dose calcineurin-inhibitor regimen. Target
trough levels of sirolimus were 4 to 8 ng/mL. Tacrolimus was
tapered down to target trough levels of 4 to 8 ng/mL and
cyclosporine to 80 to 120 ng/mL. Duration of follow-up was
18 months.
Results. At the end of follow-up, the sirolimus group showed
a significant improvement in creatinine clearance (42.6 mL/min
vs. 32.5 mL/min, P = 0.05), whereas the control group showed a
significant reduction (32.3 mL/min vs. 40.3 mL/min, P = 0.02).
The difference between the groups was statistically significant
(P < 0.0001). Acute rejection episodes occurred in 2 patients
in the sirolimus group and 1 patient in the control group (P =
NS). Pneumonia developed in 6 study patients and 4 controls;
all responded to antibiotics.
Conclusion. Sirolimus combined with low-dose calcineurin
inhibitors appears to be a safe and effective alternative im-
munosuppressive therapy to sirolimus alone in lung transplant
recipients with renal failure. Graft function is preserved, and
infection and drug toxicity rates are low.
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The development of acute and chronic renal failure is
a common complication of lung transplantation (LTX)
[1, 2]. According to a 1997 LTX registry report, 33.7%
of lung transplant recipients have renal dysfunction at
5 years after surgery [3]. The most common cause
is the use of calcineurin-inhibitor (CI) agents, the
traditional cornerstone of immunosuppressive therapy
[1, 2].
Sirolimus (SRL) is a new potent macrolide im-
munosuppressant that has a distinct mechanism of ac-
tion. Whereas tacrolimus and cyclosporine (CsA) block
calcineurin-induced interleukin (IL)-2 production and
the resultant T-cell stimulation, SRL reduces T-cell ac-
tivation at a later stage in the cell cycle by inhibiting
cytokine-induced signal transduction pathways [4]. Thus,
SRL should prevent the significant nephrotoxic potential
of tacrolimus and CsA, which is due to their calcineurin
blockade [5, 6]. In studies of renal transplant patients,
SRL was associated with similar low rejection rates and
incidence of infections to cyclosporine, and significantly
better renal function [7–10]. Furthermore, in de novo car-
diac transplant recipients, it showed excellent immuno-
suppressive efficacy and safety [11, 12].
To the best of our knowledge, only 1 uncontrolled study
has been conducted so far on the role of SRL with dosage
adjustments in LTX [13]. The sample included 20 lung and
5 heart transplant recipients with renal failure. After 30
days, 4 of the 5 dialyzed patients ceased dialysis, and 15
of the 20 patients showed improved creatinine clearance
(CrCl). There were, however, 35 infectious complications
in 16 patients, and 24 episodes of SRL-related toxicity in
17 patients. Only 15 patients remained on the drug by the
end of the study.
The aim of the present controlled pilot study was
to assess the effect of combined SRL with low-dose
CI agents in lung transplant recipients with renal
impairment.
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Table 1. Clinical characteristics of the sirolimus group
Sex/age Lung Time after Type Immunosuppression Acute rejection
Patient no. years disease LTX months of LTX regimen Statin before study
1 F/64 Emphysema 60 Lt-SLT FK/AZA/CS + 2
2 M/66 Emphysema 72 Lt-SLT CsA/AZA/CS + 0
3 M/58 PPH 60 HLT FK/AZA/CS + 1
4 M/65 Emphysema 60 Rt-SLT CsA/MMF/CS + 3
5 M/65 Emphysema 25 Rt-SLT FK/AZA/CS + 2
6 M/52 IPF 24 Rt-SLT FK/AZA/CS + 1
7 M/63 Emphysema 15 Rt-SLT FK/MMF/CS + 1
8 M/51 Emphysema 96 DLT FK/AZA/CS + 0
Abbreviations are: AZA, azathioprine; CsA, cyclosporine; CS, corticosteroids; DLT, double lung transplantation; FK, FK-506 (tacrolimus); HLT, heart-lung
transplantation; IPF, idiopathic pulmonary fibrosis; Lt SLT, left-single lung transplantation; LTX, lung transplantation; MMF, mycophenolate mofetil; PPH, primary
pulmonary hypertension; Rt SLT, right-single lung transplantation.
METHODS
Eighty-five patients underwent LTX at Rabin med-
ical center between May 1993 and March 2004.
Immunosuppresion before 1998 included a combi-
nation of prednisone, azathioprine, and CsA. Pa-
tients operated after November 1998 were treated
with prednisone, mycophenolate mofetil (MMF), and
tacrolimus.
Target trough levels at 3 months after LTX are 200 to
250 ng/mL for CsA and 8 to 12 ng/mL for tacrolimus. All
patients are routinely followed at the clinic, with complete
blood counts, blood chemistry, measurement of CrCl and
drug levels, chest radiographs, pulmonary function test-
ing, and surveillance bronchoscopies.
Of all our transplant recipients, 8 with renal impair-
ment, defined as a CrCl below 50 mL/min in 2 24-hour
urine collections, were randomly allocated to receive
a combination immunosuppression regimen with SRL
(Rapamycin; Wyeth-Ayerst, Sydney, Australia) and low-
dose CIs. SRL was started at 2 mg without a loading dose,
and adjusted according to trough levels. Target trough
levels of SRL were 4 to 8 ng/mL. Tacrolimus was tapered
down to a target trough level of 4 to 8 ng/mL, and CsA
to a target trough level of 80 to 120 ng/mL. Mean time
from the start of treatment to achievement of the tar-
get SRL level was 31 ± 1.2 months. Mean time of CI
dosage adjustments to the desired target level was 2.7 ±
0.9 months. No changes in the other immunosuppressive
medications (prednisone, MMF, or azathioprine) were
made.
The findings of the study group were compared to 8
patients with post-transplant renal impairment matched
for background and clinical characteristics who were op-
erated on during the same time period, and received the
standard immunosuppression regimen.
Both SRL and control groups had stable renal param-
eters during the 2 months prior to the study, with mean
CrCl 2 months before the study onset and at the study on-
set of 30.7 versus 32.5 mL/min and 39.7 versus 40.3 mL/
min, respectively.
All 16 patients had been treated with statins.
Statistical analysis
Continuous variables are shown as mean ± standard
deviations. Pearson correlation coefficient (r) and the sig-
nificance for it (p) were calculated for each variable be-
tween the SRL and control groups. Paired t test was used
to analyze differences in continuous variables before and




Table 1 summarizes the clinical characteristics of the
SRL group. As shown in Table 2, there were no signif-
icant differences in clinical characteristics between the
groups, as expected by the study design. Six patients in
each group had emphysema. Mean time from LTX to the
study was 51.5 ± 28 months for the SRL group, and 61 ±
36 months for the control group (P = NS). Ten episodes of
acute rejections were noted in the SRL group (Table 1).
All occurred before the study onset, with no significant
difference from the control group (Table 2).
Renal function
The renal function findings are shown in Table 3 and
Figure 1.
Both groups had normal renal function before the LTX,
with mean CrCl 80.5 ± 8.8 mL/min in the SRL group,
and 85.6 ± 19 mL/min in the control group (P = NS).
By the end of follow-up, CrCl had improved significantly
in 7 patients in the SRL group, and decreased minimally
(−4 mL/min) in 1 patient (P = 0.05 for the whole group).
By contrast, all patients in the control group showed a
decline in renal function (P = 0.02).
Mean improvement in the SRL group was 10.1 ± 7.1
mL/min, and mean decline in the control group was 7.9 ±
2.2 mL/min. The difference between the groups was sta-
tistically significant (P < 0.0001).
At onset of the study in the sirolimus group, the mean
tacrolimus dosage was 0.35 ± 0.05 mg/kg, the mean CsA
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Table 3. Creatinine clearance (mL/min) in SRL and control groups before lung transplantation and during the study period
SRL Group Control group
On starting Total On starting Total
Pre-LTX SRL 6 months 12 months 18 months effect Pre-LTX SRL 6 months 12 months 18 months effect
1 80 18 22 24 26 +8 80 30 27 25 25 −5
2 95 27 29 31 32 +5 80 36 33 30 28 −8
3 70 33 41 46 49 +16 59 36 32 30 27 −9
4 77 50 55 59 68 +18 64 46 40 36 35 −11
5 69 35 35 34 31 −4 96 47 43 40 38 −9
6 88 27 31 36 39 +12 87 37 35 35 32 −5
7 80 35 38 38 49 +14 120 49 48 45 42 −7
8 85 35 37 38 47 +12 99 41 38 35 31 −10
Table 2. Demographic data of sirolimus (SRL) and control groups
SRL group Control group
(N = 8) (N = 8) P value
Males N 6 7 NS
Age years (mean ± SD) 60.5 ± 6 56.3 ± 15 NS
Disease N
Emphysema 6 6 NS
IPF 1 1 NS
PPH 1 0 NS
Sarcoidosis 0 1 NS
Time after LTX months 51.5 ± 28 61.3 ± 36 NS
(mean ± SD)
Type of LTX
SLT 6 6 NS
DLT 1 2 NS
HLT 1 0 NS
CI base regimen
FK-506 (tacrolimus) 6 5 NS
CsA 2 3 NS
Statin treatment 8 8 NS
Acute rejection prior the study 10 9 NS
Abbreviations are: CI, calcineurin inhibitors; CsA, cyclosporine; DLT, double
lung transplantation; FK506, tacrolimus; HLT, heart-lung transplantation; IPF,
idiopathic pulmonary fibrosis; LTX, lung transplantation; NS, not significant;
PPH, primary pulmonary hypertension; SRL, sirolimus; SLT, single lung
transplantation.
dose was 6.8 ± 2.1 mg/kg, and the mean prednisone dose
11 ± 1.6 mg. At 6 months, the corresponding dosages
dropped to 0.15 ± 0.08 mg/kg, 3.8 ± 2.4 mg/kg, and
10 ± 2.5 mg, respectively, with SRL dosage at 0.043 ±
0.025 mg/kg. Thus, by adding SRL, we were able to re-
duce the dosage of CsA by 57%, and of tacrolimus by
44%. By the end of the study (18 months), the mean
through level of SRL was 4.5 ng/mL, mean tacrolimus
through level 6.8 ng/mL, and mean CsA through level
94 ng/mL. In the control group, mean tacrolimus, CsA,
and prednisone dosages were 0.12 ± 0.07 mg/kg, 4.5 ± 2.9
mg/kg, and 12 ± 3.1 mg, respectively (P = NS between
the groups) at the onset of the study and did not change
during the follow-up period. At 18 months, levels were
7.1 ng/mL and 102 ng/mL, respectively.
There were no significant differences in either group
between pre- and poststudy lipid profile, including choles-
terol and triglyceride levels (Table 4), or in white blood
cell and platelet counts, or hemoglobin values. Three
patients had significant (more than double) elevations
in triglyceride levels; all responded to medication with
dosage adjustments.
Graft function
Graft function remained stable in both groups
(Table 4).
There were 3 acute rejection episodes, 2 in the SRL
group (after 3 and 9 months), and 1 in the control group
(after 4 months). All affected patients were sensitive to
steroid pulses of prednisolone 125 mg twice daily for 3
days.
Infectious complications (pneumonia) occurred in 10
patients, 6 in the SRL group, and 4 in the control group,
between 12 and 18 months of the study period. All pa-
tients responded to antibiotics.
There were no other serious adverse events, and no
cases of myelosuppression.
DISCUSSION
This study indicates that the use of SRL in combina-
tion with low-dose CIs in lung transplant recipients may
benefit renal function. This finding is consistent with re-
cent studies in renal transplant recipients. Van Hooff et al
[9] investigated the safety and efficacy of tacrolimus and
steroids alone or in combination with 3 different doses
of SRL in 104 patients; SRL was discontinued at either
month 3 or 5. The overall safety profile was similar in
all groups, as was the incidence of infections in months
1 to 3. The 3-month rates of biopsy-proven acute rejec-
tion were 28.6% in the control group and 3.8% to 8.0%
in the tacrolimus-SRL groups (P = 0.014). The authors
concluded that tacrolimus in combination with low doses
of SRL is a very effective and safe regimen.
Baboolal [10] evaluated the safety and efficacy of SRL
plus steroids as a maintenance regimen with or without
small-dose CsA adjunctive therapy in 133 renal trans-
plant recipients. It was found that withdrawal of CsA
from a small-dose SRL maintenance regimen is safe, and
is associated with an improvement in renal function. This
study also suggested that the addition of small-dose CsA
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Fig. 1. Creatinine clearance levels (mL/min)
in the SRL and control groups during the
study period.
Table 4. Laboratory results pre-and postrandomization in sirolimus (SRL) and control groups
SRL group Control group
Variables Pre Post P value Pre Post P value
Creatinine clearancemL/min 32.5 42.6 0.05 40.3 32.2 0.02
FEV1 (% of baseline) 50 ± 17 58 ± 10 NS 52 ± 19 57 ± 15 NS
Cholesterolmg/dL 234 ± 68 217 ± 44 NS 214 ± 48 222 ± 28 NS
Triglycerides mg/dL 133 ± 31 159 ± 59 NS 113 ± 37 139 ± 50 NS
Hemoglobin g/dL 10.7 ± 1.6 11.4 ± 1.7 NS 11.7 ± 2.0 12.4 ± 1.9 NS
WBC (K/micro) 7.3 ± 2.6 7.4 ± 2.4 NS 8.3 ± 2.9 7.9 ± 2.0 NS
PLT (K/micro) 288 ± 73 284 ± 76 NS 268 ± 93 254 ± 88 NS
FEV1, forced expiratory volume at 1 second.
to a SRL maintenance regimen does not increase im-
munosuppressive efficacy.
In a parallel study of 25 heart transplant recipients with
post-transplant renal impairment, Groetzner et al [12]
reported that the CI-free regimen significantly improved
renal function. Three of the dialyzed patients were able
to stop hemodialysis.
The only study on the use of SRL in LTX was reported
by Snell et al [13]. The sample (uncontrolled) included
20 lung and 5 heart transplant patients with renal failure.
The aim of the study was to determine whether the addi-
tion of SRL allows for CI withdrawal. The results showed
that 48% of the patients ceased CI therapy following SRL
treatment, and the remainder had a substantial decrease
in dose. After 30 days, 4 of the 5 dialyzed patients ceased
dialysis, and 15 of the 20 patients showed improved renal
function. However, by contrast with our sample, the ma-
jority of transplant recipients in the study of Snell et al [13]
(N = 19, 76%) were receiving a CsA-based regimen, and
only 2 were receiving a tacrolimus-based regimen. In our
study, the benefits of SRL addition were similar for both
regimens. In addition, Snell et al [13] reported 35 infec-
tious complications and 24 episodes of SRL-related toxi-
city, whereas we observed only 3 acute rejection episodes
and 10 infectious complications. We assume that this dif-
ference is explained by the combination of low-dose CI
in our regimen, and the stable state of our patients.
Higher tacrolimus and CsA dosages were noted at the
onset of the study in the SRL group compared with the
control group. However, these differences were not sta-
tistically significant. A possible explanation could be the
short time after LTX in the SRL group (51.5 ± 28 months)
compared to the control group (61.3 ± 36, P = NS;
Table 2).
Our pilot study is limited mainly by the small sample
size. Nevertheless, the findings clearly show that SRL in
combination with low dose CI is a useful alternative to
immunosuppression with dose-adjusted SRL alone [13].
The small number of patients may explain why we failed
to find an association of lower renal function, and less re-
versibility of renal failure with longer-term CI exposure.
Recent studies in renal transplantation have indicated
that tacrolimus with adjusted-dose SRL improved long-
term graft function, and was more effective than com-
bined SRL and CsA [7, 8]. A larger, longer-term trial is
needed to address this point in LTX.
CONCLUSION
We preferred to use SRL in combination with low-dose
CIs instead of SRL alone because of the high incidence of
rejection and infections associated with lung transplants
compared to other solid organ transplants [14], in addi-
tion to the lack of safety data on SRL alone. We found
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that this combination allowed us to reduce the CI dosage
by 35% to 75%, thereby improving renal function. Graft
function was preserved during the18 months’ follow-up,
and complications were limited. Whether the improve-
ment in CrCl can be maintained over time probably de-
pends on the balance between the acute and chronic renal
damage. Larger studies are still needed to confirm these
preliminary results.
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